Hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-07-26Clinical Trial Update: Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD [Phase 2]
Phase 2 trial updates consolidation Brentuximab Vedotin in stage I/II Hodgkin lymphoma with PET positivity after 2 cycles of ABVD.
-
CLINICAL_TRIALS trial_result · 2021-07-16Clinical Trial Update: Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating carfilzomib and TGR-1202 in relapsed/refractory lymphoma and Hodgkin disease, terminated with results …
-
CLINICAL_TRIALS trial_result · 2021-07-13Clinical Trial Update: Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial update for ADCT-301 in relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-07-12Clinical Trial Update: A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) [Phase 1]
Phase 1 trial evaluating pembrolizumab (MK-3475) in blood cancers has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-06-24Clinical Trial Update: CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma [Phase 2]
Phase 2 trial evaluating CD8+ memory T-cells as consolidative therapy after donor non-myeloablative hematopoietic cell transplant in leukemi…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-06-14Clinical Trial Update: Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating chemotherapy guided by PET scan for treatment of Stage I/II Hodgkin lymphoma; results completed with posted results…
-
CLINICAL_TRIALS trial_result · 2021-06-11Clinical Trial Update: Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation [Phase 2]
Phase 2 trial update on Total Body Irradiation with or without Total Lymphoid Irradiation and Anti-Thymocyte Globulin in non-myeloablative h…
-
CLINICAL_TRIALS trial_result · 2021-06-09Clinical Trial Update: Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 study results for a combination regimen of Brentuximab Vedotin with Ifosfamide, Carboplatin, and Etoposide in relapsed or refracto…
-
CLINICAL_TRIALS trial_result · 2021-06-08Clinical Trial Update: Unrelated Umbilical Cord Blood (UBC)Transplantation [NA]
Clinical trial update for unrelated umbilical cord blood transplantation; the study is completed with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-06-01Clinical Trial Update: A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma [Phase 1, Phase 2]
This clinical trial update reports on a pediatric Phase 1/2 study of Brentuximab Vedotin combined with doxorubicin, vinblastine, and dacarba…
-
CLINICAL_TRIALS research · 2021-05-18Clinical Trial Update: Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT) [NA]
A completed clinical trial evaluating detection and quantification of differences in Hodgkin lymphoma and diffuse large B-cell lymphoma usin…
-
FDA approval · 2021-04-30FDA Approved: CARMUSTINE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application for Carmustine submitted by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. This actio…
-
CLINICAL_TRIALS trial_result · 2021-04-19Clinical Trial Update: Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating ITF2357 (histone deacetylase inhibitor) followed by mechlorethamine in relapsed/refractory Hodgkin's lymphoma; st…
-
CLINICAL_TRIALS trial_result · 2021-04-13Clinical Trial Update: A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT [Phase 2]
Phase II, multi-center, non-randomized open-label study evaluating tislelizumab with AVD regimen for newly diagnosed advanced Hodgkin lympho…
-
CLINICAL_TRIALS trial_result · 2021-03-02Clinical Trial Update: Feasibility Study of Simvastatin in Hodgkin's Lymphoma Survivors [NA]
Feasibility study of simvastatin in Hodgkin's lymphoma survivors appears terminated with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-02-21Clinical Trial Update: Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating bendamustine as a bridge to autologous or allogeneic transplant for relapsed/refractory lymphoma has completed wi…
-
CLINICAL_TRIALS withdrawal · 2021-02-15Clinical Trial Update: Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11) [Phase 3]
A Phase 3 clinical trial for very early FDG-PET/CT-response adapted therapy in advanced Hodgkin lymphoma was withdrawn.
-
CLINICAL_TRIALS trial_result · 2021-02-03Clinical Trial Update: Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma [Phase 3]
Phase 3 trial evaluating FDG-P18 PET-guided therapy versus standard therapy in previously untreated Stage I/II Hodgkin lymphoma; current sta…
-
FDA approval · 2021-01-14FDA Approved: VINCRISTINE SULFATE — Supplemental Application (Hospira, Inc.)
The FDA approved a supplemental application filed by Hospira for vincristine sulfate, a generic vincristine product.
-
CLINICAL_TRIALS trial_result · 2021-01-06Clinical Trial Update: Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma [Phase 1, Phase 2]
A completed Phase 1/2 trial evaluated panobinostat in combination with ICE chemotherapy for relapsed Hodgkin lymphoma, with results posted i…
-
CLINICAL_TRIALS trial_result · 2020-12-22Clinical Trial Update: Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease. [Phase 2]
Phase 2 trial update evaluating Brentuximab Vedotin in elderly patients with Hodgkin Lymphoma at first relapse or with primary refractory di…
-
CLINICAL_TRIALS trial_result · 2020-12-22Clinical Trial Update: Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating chemotherapy guided by PET scan in early-stage Hodgkin lymphoma (Stage I/II) has been terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2020-12-17Clinical Trial Update: Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating HCD122 in adults with Non-Hodgkin's or Hodgkin's lymphoma following at least two prior therapies has b…
-
CLINICAL_TRIALS trial_result · 2020-12-04Clinical Trial Update: CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating HSP-CAR30 CAR T-cells targeting CD30 for relapsed/refractory Hodgkin lymphoma and T-cell lymphoma is o…
-
CLINICAL_TRIALS trial_result · 2020-11-13Clinical Trial Update: HD18 for Advanced Stages in Hodgkins Lymphoma [Phase 3]
A Phase 3 clinical trial in Hodgkins Lymphoma has completed the study evaluating HD18 for advanced-stage disease.